Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapy for myositis.

C V Oddis1

  • 1University of Pittsburgh School of Medicine, Pennsylvania.

Current Opinion in Rheumatology
|December 1, 1991
PubMed
Summary
This summary is machine-generated.

Corticosteroids are the primary treatment for polymyositis and dermatomyositis. Other immunosuppressants, intravenous therapies, and less common treatments may benefit refractory patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) antibody in necrotizing myopathy: treatment outcomes, cancer risk, and role of autoantibody level.

Scandinavian journal of rheumatology·2019
Same author

Update on the pharmacological treatment of adult myositis.

Journal of internal medicine·2016
Same author

Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis.

Arthritis and rheumatism·2009
Same author

Sensory Neuropathy With Sjögren's Syndrome, Thymoma, and Hypogammaglobulinemia.

Journal of clinical neuromuscular disease·2008
Same author

Myositis-specific and -associated autoantibodies: a review from the clinical perspective.

Journal of clinical neuromuscular disease·2008
Same author

The protein tyrosine phosphatase N22 gene is associated with juvenile and adult idiopathic inflammatory myopathy independent of the HLA 8.1 haplotype in British Caucasian patients.

Arthritis and rheumatism·2008
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Area of Science:

  • Rheumatology
  • Immunology
  • Dermatology

Background:

  • Polymyositis and dermatomyositis are chronic inflammatory myopathies.
  • Current treatment primarily relies on corticosteroids.

Purpose of the Study:

  • To review the therapeutic options for polymyositis and dermatomyositis.
  • To discuss the efficacy of various immunosuppressive agents and other treatments.

Main Methods:

  • Literature review of existing therapeutic strategies.
  • Analysis of treatment outcomes for different patient populations.

Main Results:

  • Corticosteroids are the mainstay of treatment, often combined with other immunosuppressants.
  • Intravenous cyclophosphamide and cyclosporine show promise in specific cases, particularly in children.

Related Experiment Videos

  • Intravenous gamma-globulin offers short-term benefits for both pediatric and adult patients.
  • Refractory cases may be managed with plasmapheresis, total body irradiation, or thymectomy.

    • Conclusions:

    • A range of therapeutic options exists for polymyositis and dermatomyositis, with corticosteroids as the primary approach.
    • Individualized treatment strategies are necessary, considering patient age and refractory disease.
    • Further research into novel therapies may improve long-term outcomes.